Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ABL1 and Leukemia, Myelogenous, Chronic, BCR-ABL Positive:

Search results

Items: 1 to 20 of 944

1.

Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).

Möbius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1645-1650. doi: 10.1007/s00432-019-02910-6. Epub 2019 Apr 2.

PMID:
30941573
2.

Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.

Dulucq S, Etienne G, Morisset S, Klein E, Chollet C, Robbesyn F, Turcq B, Tigaud I, Hayette S, Nicolini FE, Mahon FX.

Ann Hematol. 2019 May;98(5):1159-1168. doi: 10.1007/s00277-019-03633-x. Epub 2019 Feb 23.

PMID:
30798348
3.

Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators.

Int J Hematol. 2019 Apr;109(4):426-439. doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb 14.

PMID:
30762219
4.

Single nucleotide polymorphism in PTEN-Long gene: A risk factor in chronic myeloid leukemia.

Ferri C, Weich N, Gutiérrez L, De Brasi C, Bengió MR, Zapata P, Fundia A, Larripa I.

Gene. 2019 Apr 30;694:71-75. doi: 10.1016/j.gene.2019.01.038. Epub 2019 Feb 7.

PMID:
30738963
5.

Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation.

Kim KE, Park S, Cheon S, Kim DY, Cho DJ, Park JM, Hur DY, Park HJ, Cho D.

J Immunol Res. 2018 Dec 31;2018:9580561. doi: 10.1155/2018/9580561. eCollection 2018.

6.

Detection of BCR-ABL1 fusion gene transcripts in the saliva of Nigerian patients with chronic myeloid leukemia.

Uzoma IC, Taiwo IA, Nna EO, Durosinmi MA, Ukaejiofo EO.

Niger J Clin Pract. 2019 Jan;22(1):51-55. doi: 10.4103/njcp.njcp_225_18.

7.

A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.

Hassankrishnamurthy S, Mody MD, Kota VK.

Am J Case Rep. 2019 Jan 3;20:10-14. doi: 10.12659/AJCR.911854.

8.

Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.

Xie W, Wang SA, Hu S, Xu J, Medeiros LJ, Tang G.

Cancer Genet. 2018 Dec;228-229:41-46. doi: 10.1016/j.cancergen.2018.08.002. Epub 2018 Aug 27.

PMID:
30553471
9.

Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China.

Chen LF, Yuan GL, Zhong ZD, Zou P, Li DJ, Bao Y, Ren HB, Meng L, Li WM.

Curr Med Sci. 2018 Dec;38(6):1005-1011. doi: 10.1007/s11596-018-1976-0. Epub 2018 Dec 7.

PMID:
30536062
10.

Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report.

Cerveira N, Ferreira RB, Bizarro S, Correia C, Torres L, Lisboa S, Vieira J, Santos R, Campilho F, Pinho Vaz C, Leite L, Teixeira MR, Campos A.

BMC Cancer. 2018 Dec 7;18(1):1229. doi: 10.1186/s12885-018-5100-4.

11.

[MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].

Tsubaki M.

Yakugaku Zasshi. 2018;138(12):1461-1466. doi: 10.1248/yakushi.18-00142. Review. Japanese.

12.

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Shanmuganathan N, Hughes TP.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):168-176. doi: 10.1182/asheducation-2018.1.168. Review.

PMID:
30504306
13.

Potential Leukemic Cells Engraftment After Hematopoietic Stem Cell Transplantation From Unrelated Donors With Undiagnosed Chronic Leukemia.

Kawa MP, Baumert B, Litwińska Z, Gniot M, Pius-Sadowska E, Rogińska D, Lewandowski K, Zdziarska B, Machaliński B.

Transplant Proc. 2018 Dec;50(10):3789-3796. doi: 10.1016/j.transproceed.2018.04.036. Epub 2018 Apr 18.

PMID:
30509616
14.

Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia.

McCafferty EH, Dhillon S, Deeks ED.

Paediatr Drugs. 2018 Dec;20(6):593-600. doi: 10.1007/s40272-018-0319-8. Review.

PMID:
30465234
16.

MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression.

Huan C, Jin L, Heng W, Na A, Yuming P, Xin D, Qiaoxia Z.

Leuk Res. 2018 Dec;75:1-6. doi: 10.1016/j.leukres.2018.10.012. Epub 2018 Oct 25.

PMID:
30419548
17.

Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia.

Chandran RK, Geetha N, Sakthivel KM, Aswathy CG, Gopinath P, Raj TVA, Priya G, Nair JKKM, Sreedharan H.

Gene. 2019 Feb 20;686:85-91. doi: 10.1016/j.gene.2018.11.005. Epub 2018 Nov 3.

PMID:
30399426
18.

Apheresis principles in a patient with chronic myeloid leukemia during pregnancy: challenges in cell separation and assessing transcript levels.

Lund KP, Larsen MT, Haastrup EK, Pedersen BW, Maroun LL, Andersen MT, Bjerrum OW, Fischer-Nielsen A.

Transfusion. 2019 Jan;59(1):39-45. doi: 10.1111/trf.15006. Epub 2018 Nov 5.

PMID:
30394539
19.

Primary Philadelphia chromosome positive acute myeloid leukemia: A case report.

Shao X, Chen D, Xu P, Peng M, Guan C, Xie P, Yuan C, Chen B.

Medicine (Baltimore). 2018 Nov;97(44):e12949. doi: 10.1097/MD.0000000000012949.

20.

Coexistence of t(5;17)/NPM1-RARA and t(9;22)/BCR-ABL1 in chronic myeloid leukemia at initial diagnosis.

Li Y, Shao H, Fu B.

Ann Hematol. 2019 May;98(5):1319-1321. doi: 10.1007/s00277-018-3537-9. Epub 2018 Oct 30. No abstract available.

PMID:
30377763

Supplemental Content

Loading ...
Support Center